泰它西普治疗持续性蛋白尿IgA肾病患者的随机2期试验
这项2期随机安慰剂对照试验纳入44例持续蛋白尿的IgA肾病患者,按1:1:1随机接受泰它西普160mg、240mg或安慰剂皮下注射每周一次共24周。主要终点为24周时24小时蛋白尿较基线的变化,240mg组蛋白尿较基线降低49%,与安慰剂相比差异有统计学意义(P=0.013),160mg组降低25%但未达统计学显著。不良事件各组相似,均为轻中度,未报告严重不良事件。
要点
- 泰它西普240mg组24周蛋白尿较基线降低49%,与安慰剂比较差异有统计学意义(P=0.013)。
- 泰它西普160mg组蛋白尿较基线降低25%,与安慰剂比较未达统计学显著(P=0.389)。
- 各组不良事件相似,均为轻中度,未报告严重不良事件。
核心结论
- 泰它西普治疗使IgA肾病患者蛋白尿出现有临床意义的降低,该效应提示未来肾脏病进展风险可能降低。
研究设计与样本
- 2期随机安慰剂对照试验,纳入eGFR>35 ml/min per 1.73 m2且经最佳支持治疗后蛋白尿≥0.75 g/d的IgA肾病患者44例,按1:1:1随机接受皮下泰它西普160mg、240mg或安慰剂每周一次共24周。
主要发现
- 泰它西普组血清IgA、IgG、IgM水平持续下降。
- 泰它西普240mg组蛋白尿较基线平均降低49%,与安慰剂相比变化值为0.88(95%CI -1.57至-0.20;P=0.013)。
- 泰它西普160mg组蛋白尿较基线降低25%,与安慰剂相比变化值为-0.29(95%CI -0.95至0.37;P=0.389)。
- eGFR随时间保持稳定。
- 不良事件各组相似,治疗中出现的不良事件为轻或中度,未报告严重不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To date, no specific therapies have been approved for immunoglobulin A nephropathy (IgAN) treatment. Telitacicept is a fusion protein composed of transmembrane activator and calcium-modulating cyclophilin ligand interactor and fragment crystallizable portion of immunoglobulin G (IgG), which neutralizes the B lymphocyte stimulator and a proliferation-inducing ligand. METHODS: This phase 2 randomized placebo-controlled trial aimed to evaluate the efficacy and safety of telitacicept in patients with IgAN. Participants with an estimated glomerular filtration rate (eGFR) >35 ml/min per 1.73 m2 and proteinuria ≥0.75 g/d despite optimal supportive therapy, were randomized 1:1:1 to receive subcutaneous telitacicept 160 mg, telitacicept 240 mg, or placebo weekly for 24 weeks. The primary end point was the change in 24-hour proteinuria at week 24 from baseline. RESULTS: Forty-four participants were randomized into placebo (n = 14), telitacicept 160 mg (n = 16), and telitacicept 240 mg (n = 14) groups. Continuous reductions in serum IgA, IgG, and IgM levels were observed in the telitacicept group. Telitacicept 240 mg therapy reduced mean proteinuria by 49% from baseline (change in proteinuria vs. placebo, 0.88; 95% confidence interval, -1.57 to -0.20; P = 0.013), whereas telitacicept 160 mg reduced it by 25% (-0.29; 95% confidence interval, -0.95 to 0.37; P = 0.389). The eGFR remained stable over time. Adverse events (AEs) were similar in all groups. Treatment-emergent AEs were mild or moderate, and no severe AEs were reported. CONCLUSION: Telitacicept treatment led to a clinically meaningful reduction in proteinuria in patients with IgAN in the present phase 2 clinical trial. This effect is indicative of a reduced risk for future kidney disease progression.
引用
- Lv J, Liu L, Hao C, et al. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. Kidney Int Rep. 2022. PMID: 36938094. doi:10.1016/j.ekir.2022.12.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。